Talphera, Inc. (TLPH)
TLPH Stock Price Chart
Explore Talphera, Inc. interactive price chart. Choose custom timeframes to analyze TLPH price movements and trends.
TLPH Company Profile
Discover essential business fundamentals and corporate details for Talphera, Inc. (TLPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
11 Feb 2011
Employees
13.00
Website
https://talphera.comCEO
Vincent J. Angotti
Description
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
TLPH Financial Timeline
Browse a chronological timeline of Talphera, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.07.
Earnings released on 13 May 2026
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%.
Earnings released on 23 Mar 2026
EPS came in at -$0.06 surpassing the estimated -$0.08 by +20.00%.
Earnings released on 12 Nov 2025
EPS came in at -$0.11 falling short of the estimated -$0.08 by -46.67%, while revenue for the quarter reached $1.00k .
Earnings released on 14 Aug 2025
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%.
Earnings released on 13 May 2025
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%, while revenue for the quarter reached $27.00k .
Earnings released on 31 Mar 2025
EPS came in at -$0.07 surpassing the estimated -$0.21 by +66.67%.
Earnings released on 13 Nov 2024
EPS came in at -$0.13 surpassing the estimated -$0.20 by +35.00%.
Earnings released on 14 Aug 2024
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%.
Earnings released on 14 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.28 by +42.86%.
Earnings released on 6 Mar 2024
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%, while revenue for the quarter reached $281.00k , meeting expectations.
Earnings released on 8 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.29 by +72.41%, while revenue for the quarter reached $117.00k , missing expectations by -55.51%.
Earnings released on 10 Aug 2023
EPS came in at -$0.41 surpassing the estimated -$0.53 by +22.64%, while revenue for the quarter reached $253.00k , beating expectations by +237.33%.
Earnings released on 30 Mar 2023
EPS came in at -$1.00 falling short of the estimated -$0.51 by -96.08%, while revenue for the quarter reached $252.00k , missing expectations by -94.40%.
Earnings released on 14 Nov 2022
EPS came in at -$0.94 surpassing the estimated -$1.20 by +21.67%, while revenue for the quarter reached $507.00k , missing expectations by -18.88%.
Stock split effective on 26 Oct 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2022
EPS came in at $9.60 surpassing the estimated -$1.50 by +740.00%, while revenue for the quarter reached $570.00k , beating expectations by +3.64%.
Earnings released on 16 May 2022
EPS came in at -$1.20 matching the estimated -$1.20, while revenue for the quarter reached $442.00k , missing expectations by -19.64%.
TLPH Stock Performance
Access detailed TLPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
